DOCSLIB.ORG

1/7/2020 Ndc Item Description Size Awp 62991-4021-01 690329

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1/7/2020 Ndc Item Description Size Awp 62991-4021-01 690329 current as of: 1/7/2020 NDC ITEM DESCRIPTION SIZE AWP 62991-4021-01 690329 #000 CLEAR CAPSULES 1000 $ 246.00 62991-4021-05 690330 #000 CLEAR CAPSULES 5000 $ 1,230.00 62991-4142-01 693487 #00 BLACK/RED CAPSULES 1000 $ 97.50 62991-4142-02 693494 #00 BLACK/RED CAPSULES 5000 $ 487.50 62991-4119-01 690325 #00 BLUE CAPSULES 1000 $ 97.50 62991-4119-05 690326 #00 BLUE CAPSULES 5000 $ 487.50 62991-4143-01 693488 #00 BLUE/WHITE CAPSULES 1000 $ 97.50 62991-4143-02 693495 #00 BLUE/WHITE CAPSULE 5000 $ 487.50 62991-4120-01 684615 #00 CLEAR CAPSULES 1000 $ 97.50 62991-4120-05 690574 #00 CLEAR CAPSULES 5000 $ 487.50 62991-4120-07 690943 #00 CLEAR CAPSULES 25000 $ 2,437.50 62991-4121-01 690363 #00 DARK GREEN CAPSULES 1000 $ 97.50 62991-4121-05 690364 #00 DARK GREEN CAPSULES 5000 $ 487.50 62991-4017-01 690366 #00 ORANGE CAPSULES 1000 $ 97.50 62991-4017-05 690367 #00 ORANGE CAPSULES 5000 $ 487.50 62991-4144-01 693489 #00 PINK/PINK CAPSULES 1000 $ 97.50 62991-4144-02 693496 #00 PINK/PINK CAPSULES 5000 $ 487.50 62991-4145-01 693490 #00 PURPLE/PURPLE CAPSULES 1000 $ 97.50 62991-4145-02 693497 #00 PURPLE/PURPLE CAPSULES 5000 $ 487.50 62991-4146-01 693491 #00 PURPLE/WHITE CAPSULES 1000 $ 97.50 62991-4146-02 693498 #00 PURPLE/WHITE CAPSULES 5000 $ 487.50 62991-4019-01 690357 #00 RED CAPSULES 1000 $ 97.50 62991-4019-05 690358 #00 RED CAPSULES 5000 $ 487.50 62991-4147-01 693492 #00 RED/WHITE CAPSULES 1000 $ 97.50 62991-4147-02 693499 #00 RED/WHITE CAPSULES 5000 $ 487.50 62991-4122-01 684640 #00 VEGETABLE CLEAR CAPSULES 1000 $ 150.00 62991-4122-05 690591 #00 VEGETABLE CLEAR CAPSULES 5000 $ 750.00 62991-4122-04 692582 #00 VEGETABLE CLEAR CAPSULES 70000 $ 10,500.00 62991-4156-01 693550 #00 VEGETABLE WHITE CAPSULES 1000 $ 150.00 62991-4156-02 693551 #00 VEGETABLE WHITE CAPSULES 5000 $ 750.00 62991-4020-01 684616 #00 WHITE CAPSULES 1000 $ 97.50 62991-4020-05 690575 #00 WHITE CAPSULES 5000 $ 487.50 62991-4148-01 693493 #00 YELLOW/YELLOW CAPSULES 1000 $ 97.50 62991-4148-02 693500 #00 YELLOW/YELLOW CAPSULES 5000 $ 487.50 62991-4001-01 690318 #0 BLUE CAPSULES 1000 $ 97.50 62991-4001-05 690319 #0 BLUE CAPSULES 5000 $ 487.50 62991-4002-01 684639 #0 BLUE/WHITE CAPSULES 1000 $ 97.50 62991-4002-05 690590 #0 BLUE/WHITE CAPSULES 5000 $ 487.50 62991-4004-01 684625 #0 CLEAR CAPSULES 1000 $ 97.50 62991-4004-05 690594 #0 CLEAR CAPSULES 5000 $ 487.50 62991-4004-09 691186 #0 CLEAR CAPSULES 100000 $ 9,750.00 62991-4005-01 690332 #0 GREEN TRANS/CLEAR CAPSULES 1000 $ 97.50 62991-4005-05 690333 #0 GREEN TRANS/CLEAR CAPSULES 5000 $ 487.50 62991-4008-01 690343 #0 ORANGE CAPSULES 1000 $ 97.50 62991-4008-05 690344 #0 ORANGE CAPSULES 5000 $ 487.50 62991-4114-01 690711 #0 PINK CAPSULES 1000 $ 97.50 62991-4114-05 690712 #0 PINK CAPSULES 5000 $ 487.50 62991-4117-01 690346 #0 PURPLE CAPSULES 1000 $ 97.50 62991-4117-05 690347 #0 PURPLE CAPSULES 5000 $ 487.50 LETCO MEDICAL 1 OF 43 current as of: 1/7/2020 NDC ITEM DESCRIPTION SIZE AWP 62991-4118-01 690354 #0 PURPLE/WHITE CAPSULE 1000 $ 97.50 62991-4118-05 690355 #0 PURPLE/WHITE CAPSULE 5000 $ 487.50 62991-4010-01 690322 #0 RED CAPSULES 1000 $ 97.50 62991-4010-05 690323 #0 RED CAPSULES 5000 $ 487.50 62991-4149-01 693509 #0 RED TRANS/WHITE CAPSULES 1000 $ 97.50 62991-4149-02 693510 #0 RED TRANS/WHITE CAPSULES 5000 $ 487.50 62991-4009-01 690360 #0 RED/CLEAR CAPSULES 1000 $ 97.50 62991-4009-05 690361 #0 RED/CLEAR CAPSULES 5000 $ 487.50 62991-4011-01 684610 #0 RED/WHITE CAPSULES 1000 $ 97.50 62991-4011-05 690573 #0 RED/WHITE CAPSULES 5000 $ 487.50 62991-4013-01 684638 #0 VEGETABLE CLEAR CAPSULES 1000 $ 150.00 62991-4013-05 690589 #0 VEGETABLE CLEAR CAPSULES 5000 $ 750.00 62991-4150-01 693511 #0 VEGETABLE GREEN CAPSULES 1000 $ 150.00 62991-4150-02 693517 #0 VEGETABLE GREEN CAPSULES 5000 $ 750.00 62991-4151-01 693512 #0 VEGETABLE WHITE CAPSULES 1000 $ 150.00 62991-4151-02 693518 #0 VEGETABLE WHITE CAPSULES 5000 $ 750.00 62991-4015-01 684628 #0 WHITE CAPSULES 1000 $ 97.50 62991-4015-05 690583 #0 WHITE CAPSULES 5000 $ 487.50 62991-4014-01 684631 #0 WHITE/CLEAR CAPSULES 1000 $ 97.50 62991-4014-05 690585 #0 WHITE/CLEAR CAPSULES 5000 $ 487.50 62991-4016-01 684630 #0 YELLOW CAPSULES 1000 $ 97.50 62991-4016-05 690584 #0 YELLOW CAPSULES 5000 $ 487.50 62991-4022-01 690379 #1 AQUA BLUE TRANS CAPSULES 1000 $ 97.50 62991-4022-05 690380 #1 AQUA BLUE TRANS CAPSULES 5000 $ 487.50 62991-4025-01 690385 #1 BLUE CAPSULES 1000 $ 97.50 62991-4025-05 690386 #1 BLUE CAPSULES 5000 $ 487.50 62991-4024-01 691272 #1 BLUE TRANS/PINK TRANS CAPSULES 1000 $ 97.50 62991-4024-05 691273 #1 BLUE TRANS/PINK TRANS CAPSULES 5000 $ 487.50 62991-4124-01 690388 #1 BLUE/CLEAR CAPSULES 1000 $ 97.50 62991-4124-05 690389 #1 BLUE/CLEAR CAPSULES 5000 $ 487.50 62991-4023-01 690392 #1 BLUE/PINK TRANS CAPSULES 1000 $ 97.50 62991-4023-05 690393 #1 BLUE/PINK TRANS CAPSULES 5000 $ 487.50 62991-4026-01 690395 #1 BLUE/POWDER BLUE CAPSULES 1000 $ 97.50 62991-4026-05 690396 #1 BLUE/POWDER BLUE CAPSULES 5000 $ 487.50 62991-4027-01 690398 #1 BLUE/WHITE CAPSULES 1000 $ 97.50 62991-4027-05 690399 #1 BLUE/WHITE CAPSULES 5000 $ 487.50 62991-4027-02 691265 #1 BLUE/WHITE CAPSULES 125000 $ 12,187.50 62991-4030-01 690401 #1 BROWN/IVORY CAPSULES 1000 $ 97.50 62991-4030-05 690402 #1 BROWN/IVORY CAPSULES 5000 $ 487.50 62991-4031-01 684618 #1 CLEAR CAP/WHITE CAPSULES 1000 $ 97.50 62991-4031-05 690576 #1 CLEAR CAP/WHITE CAPSULES 5000 $ 487.50 62991-4033-01 684617 #1 CLEAR CAPSULES 1000 $ 97.50 62991-4033-05 690227 #1 CLEAR CAPSULES 5000 $ 487.50 62991-4033-07 690946 #1 CLEAR CAPSULES 25000 $ 2,437.50 62991-4034-01 690407 #1 DARK GREEN CAPSULES 1000 $ 97.50 62991-4034-05 690408 #1 DARK GREEN CAPSULES 5000 $ 487.50 62991-4035-01 691236 #1 GREEN TRANS/YELLOW CAPSULES 1000 $ 97.50 62991-4035-05 691237 #1 GREEN TRANS/YELLOW CAPSULES 5000 $ 487.50 62991-4037-01 684634 #1 GREEN/ORANGE CAPSULE 1000 $ 97.50 LETCO MEDICAL 2 OF 43 current as of: 1/7/2020 NDC ITEM DESCRIPTION SIZE AWP 62991-4037-05 690305 #1 GREEN/ORANGE CAPSULE 5000 $ 487.50 62991-4038-01 690410 #1 GREEN/WHITE CAPSULES 1000 $ 97.50 62991-4038-05 690411 #1 GREEN/WHITE CAPSULES 5000 $ 487.50 62991-4039-01 684632 #1 GREEN/YELLOW CAPSULES 1000 $ 97.50 62991-4039-05 690451 #1 GREEN/YELLOW CAPSULES 5000 $ 487.50 62991-4040-01 690413 #1 GREY/PINK CAPSULES 1000 $ 97.50 62991-4040-05 690414 #1 GREY/PINK CAPSULES 5000 $ 487.50 62991-4041-01 690416 #1 IVORY CAPSULES 1000 $ 97.50 62991-4041-05 690417 #1 IVORY CAPSULES 5000 $ 487.50 62991-4043-01 691015 #1 MAROON TRANS/CLEAR CAPSULES 1000 $ 97.50 62991-4043-05 691016 #1 MAROON TRANS/CLEAR CAPSULES 5000 $ 487.50 62991-4044-01 691195 #1 MINT GREEN CAPSULES 1000 $ 97.50 62991-4044-05 691196 #1 MINT GREEN CAPSULES 5000 $ 487.50 62991-4044-02 695885 #1 MINT GREEN CAPSULES 125000 $ 12,187.50 62991-4046-01 690419 #1 ORANGE CAPSULES 1000 $ 97.50 62991-4046-05 690420 #1 ORANGE CAPSULES 5000 $ 487.50 62991-4045-01 684633 #1 ORANGE/CLEAR CAPSULES 1000 $ 97.50 62991-4045-05 690452 #1 ORANGE/CLEAR CAPSULES 5000 $ 487.50 62991-4047-01 690443 #1 ORANGE/YELLOW CAPSULES 1000 $ 97.50 62991-4047-05 690444 #1 ORANGE/YELLOW CAPSULES 5000 $ 487.50 62991-4050-01 690446 #1 PINK CAPSULES 1000 $ 97.50 62991-4050-05 690447 #1 PINK CAPSULES 5000 $ 487.50 62991-4049-01 690449 #1 PINK/CLEAR CAPSULES 1000 $ 97.50 62991-4049-05 690450 #1 PINK/CLEAR CAPSULES 5000 $ 487.50 62991-4125-01 690527 #1 PINK/POWDER BLUE CAPSULES 1000 $ 97.50 62991-4125-05 690528 #1 PINK/POWDER BLUE CAPSULES 5000 $ 487.50 62991-4051-01 690530 #1 PINK/WHITE CAPSULES 1000 $ 97.50 62991-4051-05 690531 #1 PINK/WHITE CAPSULES 5000 $ 487.50 62991-4052-01 690533 #1 PINK/YELLOW CAPSULES 1000 $ 97.50 62991-4052-05 690534 #1 PINK/YELLOW CAPSULES 5000 $ 487.50 62991-4053-01 690422 #1 POWDER BLUE CAPSULES 1000 $ 97.50 62991-4053-05 690423 #1 POWDER BLUE CAPSULES 5000 $ 487.50 62991-4055-01 690425 #1 PURPLE CAPSULES 1000 $ 97.50 62991-4055-05 690426 #1 PURPLE CAPSULES 5000 $ 487.50 62991-4055-02 692713 #1 PURPLE CAPSULES 125000 $ 12,187.50 62991-4057-01 690434 #1 RED CAPSULES 1000 $ 97.50 62991-4057-05 690435 #1 RED CAPSULES 5000 $ 487.50 62991-4056-01 690428 #1 RED/BLUE CAPSULES 1000 $ 97.50 62991-4056-05 690429 #1 RED/BLUE CAPSULES 5000 $ 487.50 62991-4058-01 690431 #1 RED/WHITE CAPSULES 1000 $ 97.50 62991-4058-05 690432 #1 RED/WHITE CAPSULES 5000 $ 487.50 62991-4059-01 684636 #1 VEGETABLE CLEAR CAPSULES 1000 $ 150.00 62991-4059-05 690587 #1 VEGETABLE CLEAR CAPSULES 5000 $ 750.00 62991-4152-01 693513 #1 VEGETABLE WHITE CAPSULES 1000 $ 150.00 62991-4152-02 693519 #1 VEGETABLE WHITE CAPSULES 5000 $ 750.00 62991-4061-01 684620 #1 WHITE CAPSULES 1000 $ 97.50 62991-4061-05 690578 #1 WHITE CAPSULES 5000 $ 487.50 62991-4061-02 691389 #1 WHITE CAPSULES 125000 $ 12,187.50 62991-4060-01 684619 #1 WHITE/CLEAR CAPSULES 1000 $ 97.50 LETCO MEDICAL 3 OF 43 current as of: 1/7/2020 NDC ITEM DESCRIPTION SIZE AWP 62991-4060-05 690577 #1 WHITE/CLEAR CAPSULES 5000 $ 487.50 62991-4063-01 690437 #1 YELLOW CAPSULES 1000 $ 97.50 62991-4063-05 690438 #1 YELLOW CAPSULES 5000 $ 487.50 62991-4065-01 684637 #2 CLEAR CAPSULES 1000 $ 97.50 62991-4065-05 690588 #2 CLEAR CAPSULES 5000 $ 487.50 62991-4065-06 691486 #2 CLEAR CAPSULES 150000 $ 14,625.00 62991-4153-01 693514 #2 VEGETABLE WHITE CAPSULES 1000 $ 150.00 62991-4153-02 693520 #2 VEGETABLE WHITE CAPSULES 5000 $ 750.00 62991-4067-01 690461 #3 BLUE CAPSULES 1000 $ 97.50 62991-4067-05 690462 #3 BLUE CAPSULES 5000 $ 487.50 62991-4067-03 691408 #3 BLUE CAPSULES 225000 $ 21,937.50 62991-4068-01 690458 #3 BLUE/CLEAR CAPSULES 1000 $ 97.50 62991-4068-05 690459 #3 BLUE/CLEAR CAPSULES 5000 $ 487.50 62991-4069-01 690464 #3 BLUE/WHITE CAPSULES 1000 $ 97.50 62991-4069-05 690465
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Quality Issues in Caring for Older People
    Doctoral Thesis - Tesis Doctoral Quality issues in caring for older people: • Appropriateness of transition from long-term care facilities to acute hospital care • Potentially inappropriate medication: development of a European list Anna Renom Guiteras Prof. Gabriele Meyer Prof. Ramón Miralles Basseda Martin Luther University Halle-Wittenberg Universitat Autònoma de Barcelona Halle (Saale) & Barcelona, Catalonia University of Witten/Herdecke Spain Witten Germany Programa de doctorat en Medicina Departament de Medicina, Facultat de Medicina Universitat Autònoma de Barcelona Barcelona, 2015 13 Contents 15 1. Introduction • Research context • Background of the research topics • Pesetaio of the ailes 23 2. Summary and discussion of the results 31 3. Conclusions 37 4. References 47 5. Articles • Article 1: Renom-Guiteras A, Uhrenfeldt L, Meyer G, Mann E. Assessment tools for determining appropriateness of admission to acute care of persons transferred from long-term care facilities: a systematic review. BMC Geriatr. 2014;14:80 • Article 2: Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71(7):861-75 77 6. Annexes • Annex 1.1 (article 1) - Additional file 1: Studies dealing with assessment tools for determining appropriateness of hospital admissions among residents of LTC facilities. • Annex 1.2 (article 1) - Additional file 2: Characteristics of the assessment tools for determining appropriateness of hospital admissions among residents of LTC facilities. • Annex 2.1 (article 2) - Appendix 1: Complete EU(7)-PIM list • Annex 2.2 (article 2) - Appendix 2: Questionable Potentially Inappropriate Medications (Questionable PIM): results of the Delphi survey.
    [Show full text]
  • Identification of Potentially Inappropriate Medications with Risk
    Journal name: Clinical Interventions in Aging Article Designation: Original Research Year: 2019 Volume: 14 Clinical Interventions in Aging Dovepress Running head verso: Aguiar et al Running head recto: Aguiar et al open access to scientific and medical research DOI: 192252 Open Access Full Text Article ORIGINAL RESEARCH Identification of potentially inappropriate medications with risk of major adverse cardiac and cerebrovascular events among elderly patients in ambulatory setting and long-term care facilities This article was published in the following Dove Medical Press journal: Clinical Interventions in Aging João Pedro Aguiar1 Purpose: Cardiovascular diseases (CVDs) are extremely common among the elderly, but Luís Heitor Costa2 information on the use of potentially inappropriate medications (PIMs) with cardiovascular Filipa Alves da Costa3,4 risk is scarce. We aimed to determine the prevalence of PIMs with risk of cardiac and cere- Hubert GM Leufkens5 brovascular adverse events (CCVAEs), including major adverse cardiac and cerebrovascular Ana Paula Martins1 events (MACCE). Patients and methods: A cross-sectional study was performed using a convenience sample 1Research Institute for Medicines (iMED.ULisboa), Faculdade de from four long-term care facilities and one community pharmacy in Portugal. Patients were For personal use only. Farmácia, Universidade de Lisboa, included if they were aged 65 or older and presented at least one type of medication in their 2 Lisboa, Portugal; Serviço de medical and pharmacotherapeutic records from 2015 until December 2017. The main outcome Medicina Interna, Centro Hospitalar Psiquiátrico de Lisboa (CHPL), Lisboa, was defined as the presence of PIMs with risk of MACCE and was assessed by applying a Portugal; 3Centro de Investigação PIM-MACCE list that was developed from a previous study.
    [Show full text]
  • Synthetic Repurposing of Drugs in Hypertension: a Datamining Method Based on Association Rules and a Novel Discrete Algorithm
    Synthetic Repurposing of Drugs in Hypertension: a Datamining Method Based on Association Rules and a Novel Discrete Algorithm Yosef Masoudi-Sobhanzadeh University of Tehran Ali Masoudi-Nejad ( [email protected] ) https://orcid.org/0000-0003-0659-5183 Methodology article Keywords: Data mining, Drug repurposing, Hypertension, Optimization algorithm, Synthetic repurposing Posted Date: May 11th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-25124/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Version of Record: A version of this preprint was published on July 16th, 2020. See the published version at https://doi.org/10.1186/s12859-020-03644-w. Synthetic Repurposing of Drugs in Hypertension: a Datamining Method Based on Association Rules and a Novel Discrete Algorithm Yosef Masoudi-Sobhanzadeh1,a, Ali Masoudi-Nejad1,* 1. Laboratory of Systems Biology and Bioinformatics (LBB), Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran a [email protected] *Corresponding Author Ali Masoudi-Nejad, Ph.D, Laboratory of Systems Biology and Bioinformatics (LBB) Institute of Biochemistry and Biophysics University of Tehran, Tehran, Iran. E-mail: [email protected] WWW: http://LBB.ut.ac.ir 1 Abstract Background: Drug repurposing aims to detect the new benefits of the existing drugs and to reduce the spent time and cost of the drug development projects. Although synthetic repurposing of drugs may be more useful than single repurposing in terms of reducing toxicity and enhancing efficacy, the researchers have not taken it into account. To address the issue, a novel datamining method is introduced and applied to the repositioning of drugs in hypertension (HT), which is a serious medical condition and therefore needs to be dealt with effectively through making some improved treatment plans to help cure it.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Dementia Summary
    Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Number 97 Pharmacological Treatment of Dementia Summary Introduction 1. Does pharmacotherapy for dementia syndromes improve cognitive symptoms and The focus of this review is the pharmacological outcomes? treatment of dementia. Pharmacotherapy is often 2. Does pharmacotherapy delay cognitive the central intervention used to improve deterioration or delay disease onset of symptoms or delay the progression of dementia dementia syndromes? syndromes. The available agents vary with respect 3. Are certain drugs, including alternative to their therapeutic actions, and are supported by medicines (non-pharmaceutical), more varying levels of evidence for efficacy. This report effective than others? is a systematic evaluation of the evidence for 4. Do certain patient populations benefit more pharmacological interventions for the treatment from pharmacotherapy than others? of dementia in the domains of cognition, global 5. What is the evidence base for the treatment function, behavior/mood, quality of life/activities of ischemic vascular dementia (VaD)? of daily living (ADL) and caregiver burden. This review considers different types of Many medications have been studied in dementia populations (not just Alzheimer’s dementia patients. These agents can be classified Disease [AD]) in subjects from both community into three broad categories: and institutional settings. The studies eligible in 1. Cholinergic neurotransmitter modifying this systematic review were restricted to parallel agents, such as acetylcholinesterase inhibitors. RCTs of high methodological quality. 2. Non-cholinergic neurotransmitters/ neuropeptide modifying agents. Methods 3. Other pharmacological agents. A team of content specialists was assembled Although only five agents have been approved from both international and local experts.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open: first published as 10.1136/bmjopen-2020-039747 on 22 October 2020. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2020-039747 on 22 October 2020. Downloaded from Development and internal validation of prognostic models to predict negative health outcomes in older patients with multimorbidity and polypharmacy in general practice ForJournal: peerBMJ Open review only Manuscript ID bmjopen-2020-039747 Article Type: Original research Date Submitted by the 24-Apr-2020
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Review of Existing Classification Efforts
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.1.1 Review of existing classification efforts Due date of deliverable: (15.01.2008) Actual submission date: (07.02.2008) Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UGent Revision 1.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public X PP Restricted to other programme participants (including the Commission Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) Task 4.1 : Review of existing classification efforts Authors: Kristof Pil, Elke Raes, Thomas Van den Neste, An-Sofie Goessaert, Jolien Veramme, Alain Verstraete (Ghent University, Belgium) Partners: - F. Javier Alvarez (work package leader), M. Trinidad Gómez-Talegón, Inmaculada Fierro (University of Valladolid, Spain) - Monica Colas, Juan Carlos Gonzalez-Luque (DGT, Spain) - Han de Gier, Sylvia Hummel, Sholeh Mobaser (University of Groningen, the Netherlands) - Martina Albrecht, Michael Heiβing (Bundesanstalt für Straßenwesen, Germany) - Michel Mallaret, Charles Mercier-Guyon (University of Grenoble, Centre Regional de Pharmacovigilance, France) - Vassilis Papakostopoulos, Villy Portouli, Andriani Mousadakou (Centre for Research and Technology Hellas, Greece) DRUID 6th Framework Programme Deliverable D.4.1.1. Revision 1.0 Review of Existing Classification Efforts Page 2 of 127 Introduction DRUID work package 4 focusses on the classification and labeling of medicinal drugs according to their influence on driving performance.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Practice Parameter: Management of Dementia (An Evidence-Based Review)
    PRACTICE PARAMETER: MANAGEMENT OF DEMENTIA (AN EVIDENCE-BASED REVIEW) Report of the Quality Standards Subcommittee of the American Academy of Neurology R.S. Doody, MD, PhD; J.C. Stevens, MD; C. Beck, RN, PhD; R.M. Dubinsky, MD; J.A. Kaye, MD; L. Gwyther, MSW; R.C. Mohs, PhD; L.J. Thal, MD; P.J. Whitehouse, MD, PhD; S.T. DeKosky, MD; and J.L. Cummings, MD Article abstract—Objective: To define and investigate key issues in the management of dementia and to make literature- based treatment recommendations. Methods: The authors searched the literature for four clinical questions: 1) Does pharmacotherapy for cognitive symptoms improve outcomes in patients with dementia? 2) Does pharmacotherapy for noncognitive symptoms improve outcomes in patients with dementia? 3) Do educational interventions improve outcomes in patients and/or caregivers? 4) Do other nonpharmacologic interventions improve outcomes in patients and/or caregivers? Results: Cholinesterase inhibitors benefit patients with AD (Standard), although the average benefit appears small; vitamin E likely delays the time to clinical worsening (Guideline); selegiline, other antioxidants, anti- inflammatories, and estrogen require further study. Antipsychotics are effective for agitation or psychosis in patients with dementia where environmental manipulation fails (Standard), and antidepressants are effective in depressed patients with dementia (Guideline). Educational programs should be offered to family caregivers to improve caregiver satisfaction and to delay the time to nursing home placement (Guideline). Staff of long-term care facilities should also be educated about AD to minimize the unnecessary use of antipsychotic medications (Guideline). Behavior modification, scheduled toileting, and prompted voiding reduce urinary incontinence (Standard). Functional independence can be increased by graded assistance, skills practice, and positive reinforcement (Guideline).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0050713 A1 Malakhov Et Al
    US 2015.0050713A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0050713 A1 Malakhov et al. (43) Pub. Date: Feb. 19, 2015 (54) TECHNOLOGY FOR THE PREPARATION OF Publication Classification MCROPARTICLES (51) Int. Cl. (71) Applicant: Ansun Biopharma, Inc., San Diego, CA CI2N 9/96 (2006.01) (US) CI2N 7/00 (2006.01) CI2N IS/II3 (2006.01) (72) Inventors: Michael P. Malakhov, San Francisco, C07D 305/.4 (2006.01) CA (US); Fang Fang, Rancho Santa Fe, C07K 4/765 (2006.01) CA (US) C07K9/00 (2006.01) (52) U.S. Cl. CPC ................ CI2N 9/96 (2013.01); C07K 14/765 (21) Appl. No.: 14/341,502 (2013.01); C07K9/008 (2013.01): CI2N 15/113 (2013.01); C07D 305/14 (2013.01); (22) Filed: Jul. 25, 2014 CI2N 7/00 (2013.01); C12N 2770/00051 (2013.01) O O USPC ........... 435/188: 530/363; 530/350, 530/367; Related U.S. Application Data 530/385:536/16.8; 536/13.7: 540/336; 530/317; (63) Continuation of application No. 13/874,424, filed on 536/24.5; 530/328; 552/203; 549/510; 435/238 Apr. 30, 2013, now abandoned, which is a continuation (57) ABSTRACT of application No. 13/250,653, filed on Sep. 30, 2011, Mi h duced b tacti lution of a now abandoned, which is a continuation of application 1crospneres are produced by contacting a sol No. 12/179.520, filed on Jul 24, 2008, now aban- macromolecule or small molecule in a solvent with an ant1 doned sa- 1 ws s s Solvent and a counterion, and chilling the solution.
    [Show full text]